GlassScriptPhysician profile
Pierre M George
NPI 1285743781
$450.40
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.26 · 2020: $13.13 · 2022: $97.31 · 2023: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $73.16 | 2019-2023 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $59.32 | 2022-2023 | Tremfya, Simponi, Remicade |
| Genzyme Corporation | $55.11 | 2022-2023 | |
| Dermavant Sciences, INC. | $49.45 | 2023 | Vtama |
| Incyte Corporation | $48.41 | 2022-2023 | Opzelura |
| Celgene Corporation | $36.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.17 | 2022-2023 | Sotyktu |
| Amgen INC. | $20.03 | 2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $19.07 | 2023 | Winlevi |
| Mylan Institutional INC. | $17.03 | 2023 | Hulio |
| Sandoz INC. | $16.21 | 2023 | Hyrimoz |
| Ucb, INC. | $13.50 | 2023 | Cimzia |
| Prugen, INC. Pharmaceuticals | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.